

advances.sciencemag.org/cgi/content/full/5/2/eaau6849/DC1

## Supplementary Materials for

# Nonspecific effects of oral vaccination with live-attenuated Salmonella Typhi strain Ty21a

S. H. Pennington\*, D. M. Ferreira, E. Caamaño-Gutiérrez, J. Reiné, C. Hewitt, A. D. Hyder-Wright, S. B. Gordon, M. A. Gordon\*

\*Corresponding author. Email: shaun.pennington@lstmed.ac.uk (S.H.P.); magordon@liverpool.ac.uk (M.A.G.)

Published 27 February 2019, *Sci. Adv.* **5**, eaau6849 (2019) DOI: 10.1126/sciadv.aau6849

#### This PDF file includes:

Supplementary Materials and Methods

#### **Supplementary Materials and Methods**

### Peripheral blood mononuclear cell (PBMC) isolation

Peripheral blood samples were collected in lithium heparin Vacutainers (BD Biosciences). Samples were layered on Ficoll-Paque PLUS using LeucoSep centrifuge tubes and centrifuged at 800 g for 18 minutes at room temperature without brake. Cells were isolated using a sterile Pasteur pipette, washed twice (centrifuged at 250 g for 10 minutes) with HBSS<sup>-/-</sup> and resuspended in 10mL HBSS<sup>-/-</sup>. A sample of the cell suspension was diluted 1:1 by adding 10  $\mu$ L of the cell suspension to 10  $\mu$ L 0.4% Trypan Blue. The number of viable cells was then enumerated.

Cells were stored using CTL-Cryo ABC media. Cells were washed once (centrifuged at 250 g for 10 minutes) with HBSS<sup>-/-</sup> and the cell pellet resuspended in CryoC at a concentration of  $2 \times 10^7$  cells/mL. Samples were then placed on ice and an equal volume of CryoA:CryoB (4:1) was slowly added to achieve a final concentration of  $1 \times 10^7$  cells/mL. The cell suspension was aliquoted into cryovials in 1 mL volumes. Cryovials were then placed in a cooled Mr. Frosty freezing container and transferred to -80°C. After 24 hours cryovials were transferred on dry ice to -200°C storage.

Cells were removed from -200°C storage and incubated at 37°C for 10 minutes. Cryovials were inverted twice and the contents of the cryovial transferred into 15 mL Falcon tubes. Cryovials were washed once with 1 mL prewarmed DNase I medium in order to collect any remaining cells. An additional 8 mL prewarmed DNase I medium was added to the 15 mL Falcon tubes at a rate of 1 mL every five seconds. Samples were washed twice (centrifuged at 330 g for 10 minutes) with prewarmed DNase I medium and resuspended in 600  $\mu$ L prewarmed complete medium. A sample of the cell suspension was diluted 1:1 by adding 10  $\mu$ L of the cell suspension to 10  $\mu$ L 0.4% Trypan Blue. The number of viable cells was then enumerated.

The concentration of the cell suspension was adjusted with complete medium to  $1 \times 10^7$  cells/mL. 100 µL of the cell suspension was then added to each well of a 96-well plate, as required. Cells were then 'rested' overnight at 37°C in 5% CO<sub>2</sub>. The following day, plates were centrifuged at 330 g for 10 minutes, the supernatant removed and the cells in each well resuspended in 100 µL prewarmed complete medium.

### Flow cytometric analyses

For phenotypic analysis, PBMCs were washed and stained for viability (Vivid®; Invitrogen) and surface phenotype using antibodies specific to CD14-PerCP/Cy5.5 (M $\phi$ P9; BD Biosciences), CD16-APC/Cy7 (Fc $\gamma$ RIII; BioLegend), CD64-BV605 (HI10a; BioLegend), CD18-PE/Cy7 (TS1/18; BioLegend), CD11b-AF700 (ICRF44; BD Biosciences), CD11c-Pacific Blue (Bu15; BioLegend), CD123-BV711 (6H6; BioLegend), CD206-PE/CF594 (19.2; BD Biosciences), CD284-APC (HTA125; BioLegend), CD285-FITC (624915; R&D Systems), CD303-PE (201A; BioLegend) and CD161-BV785 (L243; BioLegend). Cells were washed and stored in the absence of light at 4°C until data were acquired using a FACSAria III flow cytometer (BD Biosciences).

For intracellular cytokine analysis, following stimulation and incubation, PBMCs were washed and stained for viability (Vivid®; Invitrogen) and surface phenotype using antibodies specific to CD3-APC/H7 (SK7; BD Biosciences), CD4-PerCP/Cy5.5 (SK3; BioLegend), CD8-BV650 (SK1; BioLegend), CD14-APC/H7 (MφP9; BD Biosciences), CD20-Pacific Blue (2H7;

BioLegend), CD161-BV785 (HP-3G10; BioLegend), TCRγδ-PE/Cy7 (11F2; BD Biosciences) and Vα7.2-PE/Dazzle594 (3C10; BioLegend). Following fixation and permeabilisation (Cytofix/Cytoperm<sup>TM</sup>; BD Biosciences), cells were stained for intracellular interferon (IFN)-γ-PE (4S.B3; BioLegend), tumour necrosis factor (TNF)-α-FITC (MAb11; BioLegend), interleukin (IL)-17A-AF700 (N49-653; BD Biosciences) and IL-4-BV711 (MP4-25D2; BD Biosciences) and transforming growth factor (TGF)-β-APC (TW4-6h10; BioLegend). Cells were washed in Perm/Wash<sup>TM</sup> (BD Biosciences), resuspended in CellFIX<sup>TM</sup> (BD Biosciences), and stored in the absence of light at 4°C until data were acquired using a FACSAria III flow cytometer (BD Biosciences).

Compensation beads (BD Biosciences) were used to create compensation matrices and sequential cell isolation used to identify populations of interest (Fig. 1 and Fig. 3). IFN- $\gamma^+$ , TNF- $\alpha^+$ , IL-17A<sup>+</sup>, IL-4<sup>+</sup> and TGF- $\beta^+$  populations were positively identified using FlowJo version 10 (Treestar Inc.).